HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: Romidespsin is a cyclicpeptide HDAC inhibitor which is approved for cutaneous T cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL).